Clinical-stage biopharmaceutical firm Deciphera Pharmaceuticals has commenced a Phase I clinical trial of DCC-3014 for the treatment of patients with advanced malignancies.
Equipped with the firm’s Switch Control Inhibitor platform, DCC-3014 is a highly selective, small-molecule colony stimulating factor 1 receptor (CSF1R) inhibitor designed to act as a highly specific macrophage immunomodulatory agent.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The multi-centre Phase I trial will evaluate the safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of DCC-3014 in approximately 55 patients across both dose-escalation and expansion phases.
Deciphera president and chief executive officer Michael Taylor said: “We are excited to initiate this first-in-human Phase I clinical trial of DCC-3014, our small molecule switch control inhibitor of CSF1R.
“Preclinical data from a number of cancer models have demonstrated that DCC-3014 has potent macrophage checkpoint inhibitory activity.
“We believe DCC-3014 has great potential as a novel immunomodulatory agent and an important new therapy for cancer patients.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to Deciphera chief medical officer Oliver Rosen, DCC-3014 blocks immune checkpoints of macrophage associated with the tumour microenvironment and was found to have additive or synergistic immunomodulatory activity in combination with PD-1 inhibitor in multiple preclinical models.
The drug has also demonstrated a potent inhibition of the CSF1R in the models.
Deciphera primarily develops therapeutic agents to address the drug resistance mechanisms that mitigate the rate and / or durability of response in cancer patients.
The agents are designed to target enzymes called kinases, which are reported to be involved in the growth and spread of several cancers.
